Analysis of relation between 18F-FDG PET/CT and clinical manifestations for patients with bone metastases from prostate cancer
10.7687/j.issn1003-8868.2017.10.069
- VernacularTitle:前列腺癌骨转移18F-FDG PET/CT表现与临床资料的相关分析
- Author:
Xiang CHEN
1
;
Jian-Hua SONG
;
Chang-Cun LIU
;
Jin-Hua ZHAO
Author Information
1. 上海交通大学附属第一人民医院核医学科
- Keywords:
prostate cancer;
metastatic carcinoma of bone;
PET/CT;
prostate-specific antigen;
tumor differentiation
- From:
Chinese Medical Equipment Journal
2017;38(10):69-72
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the relationship between 18F-FDG PET/CT manifestations,tumor differentiation and PSA for the patients with bone metastases from prostate cancer.Methods Retrospective analysis was executed on the distribution,number and density of bone metastases tumor and FDG uptake as well as the relationship between serum PSA,FDG uptake of bone metastases focus,type of bone metastases and the involved range.Results Of the 25 cases,there were 8 ones of poorly differentiated carcinoma and 17 ones of moderately differentiated carcinoma.All the patients had serum PSA higher than 10 μg/ml,of whom there were 19 ones had the PSA not lower than 20 μg/ml.Eight patients with bone metastases restrained in the pelvis and lower lumbar vertebra,and the remained 17 ones had multiple or diffuse bone metastases.Fisher's exact test showed that non-osteoblastic metastases were more common in low-and medium-differentiation patients (P=0.022),the typing of bone metastases had no relationship with the enhancement of PSA,and there were no statistical differences between the involved ranges of the patients.Conclusion Bone metastases from prostate cancer often occurs in the patient with obviously enhanced PSA and poorly differentiation.18F-FDG PET/CT behaves well in the early diagnosis of bone metastases from prostate cancer.18F-FDG PET/CT manifestations differ with the differentiation of carcinoma,poorly differentiated carcinoma shows non-osteoblastic metastases and high FDG uptake,and moderately differentiated carcinoma appears as osteoblastic metastases and low FDG uptake.There is no confirmed correlation between PET/CT manifestation and total serum PSA for the patients with bone metastases from prostate cancer.
